Form 8-K - Current report:
SEC Accession No. 0000950170-25-046163
Filing Date
2025-03-27
Accepted
2025-03-27 16:48:21
Documents
13
Period of Report
2025-03-27
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K acrv-20250327.htm   iXBRL 8-K 45285
2 EX-99.1 acrv-ex99_1.htm EX-99.1 186080
3 GRAPHIC img28311487_0.jpg GRAPHIC 55869
  Complete submission text file 0000950170-25-046163.txt   443253

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT acrv-20250327.xsd EX-101.SCH 26943
15 EXTRACTED XBRL INSTANCE DOCUMENT acrv-20250327_htm.xml XML 5116
Mailing Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 617-207-8979
Acrivon Therapeutics, Inc. (Filer) CIK: 0001781174 (see all company filings)

EIN.: 825125532 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41551 | Film No.: 25780127
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)